Regulatory review company Advarra has launched an enhancement of its Longboat platform that includes an online patient portal to improve collaboration between patients, sponsors and CROs.
The addition allows trial sites to share documents such as signed informed consent forms and lab results with patients, the company said in an Oct. 4 press release. Patients also get access through the portal to study information, study contacts, informational videos and other tools.
“We've been listening to sites who are drowning in administrative tasks, repeatedly entering the same information, having to log into multiple systems or feeling out of the loop with direct communication between the sponsor and patient," Elisa Cascade, Advarra’s chief product officer, said in the release. “A connected system with site, sponsor, CRO, and patient access provides visibility to all while preserving the site-patient relationship.”
The Longboat platform is used in more than 70 countries covering about 20,000 trial sites, the company said. The patient portal is expected to be available as part of Longboat 2.2 later this month.
Last October, Advarra recorded a milestone by surpassing the 1,000 mark for gene therapy research sites. Those locations use the company’s Gene Therapy Ready platform, which launched in 2021, and include facilities conducting clinical trials for genetically engineered vaccines, gene-modified cellular therapies and gene therapies.